Biotechnology
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications Excerpt from the Press Release: CARLSBAD, Calif., Nov. 30, 2021 /PRNewswire/ — For research applications requiring highly precise genome editing, including engineering CAR T cells and creating cellular models for disease discovery, the Invitrogen TrueCut HiFi Cas9 Protein* significantly minimizes off-target events while retaining maximum on-target…
Read MoreA consortium of quantum computing companies including Medicines Discovery Catapult (MDC) has secured a £6.85 million grant for a project that is looking to improve drug discovery in cancer. Excerpt from the Press Release: The consortium is being led by SEEQC and will look to accelerate the use of quantum computing within pharmaceutical research to…
Read MoreThe Infection Innovation Consortium (iiCON) and organ-on-a-chip company (OOC) CN BIO have launched a research collaboration to validate the next generation of Covid-19 research tools. Excerpt from the Press Release: Led by the Liverpool School of Tropical Medicine (LSTM) iiCON is a £174 million programme that brings together industry, academia, and clinicals to accelerate the…
Read MoreThe cancer therapy may also affect the protein building process, not just cause muscles to degrade Date:November 18, 2021 Source:Penn State Summary:Previous research has found that chemotherapy can trigger muscle loss in people living with cancer, but a new study out of found it may also affect the way the body builds new muscle —…
Read MoreBiologists show that helper immune cells disguised as cancer cells can help rejuvenate T cells that attack tumors Date:November 19, 2021 Source:Massachusetts Institute of Technology Summary:Researchers uncovered a new way to indirectly activate T cells that can target tumors, by recruiting a population of helper immune cells called dendritic cells. Excerpt from the Press Release:…
Read MoreExcerpt from the Press Release: KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this…
Read MoreSG-5-00455 delivered directly to the gut via engineered L. lactis system restores barrier function and improves mucosal healing in an ulcerative colitis model Company also participates as new Crohn’s & Colitis Foundation Corporate Circle member to support Foundation’s IBD treatment, awareness and patient engagement initiatives Excerpt from the Press Release: BRISBANE, Calif. – November 18,…
Read MoreNew, Single-arm Phase 3 Study Expected to Initiate in Early 2022 Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, is announcing at its virtual Spotlight Event being held today that, following recent discussions with the…
Read MoreInitial Safety and Efficacy Data for NKTR-255, a Novel IL-15 Agonist, in Combination with Cetuximab in Solid Tumors Presented in Late-Breaking Abstract Session SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. Excerpt from the Press Release: Initial clinical…
Read More–Publication highlights first ever, most comprehensive data-driven neurobiological mapping of the mind– –Findings, published in Nature Neuroscience, validate Alto’s rigorous high-science approach and may be translated to future drug discovery and development– –Intellectual property has been exclusively licensed to Alto by Stanford– Excerpt from the Press Release: LOS ALTOS, Calif.–(BUSINESS WIRE)–Alto Neuroscience today announced the publication of the…
Read More